Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study.
Malignant thyroid tumors after iodine-131 therapy: a retrospective cohort study.
复制标题
碘 131 治疗后的恶性甲状腺肿瘤：一项回顾性队列研究。
DOI：
--
复制
发表时间：
1980
影响因子：
158.5
通讯作者：
G. Lundell
中科院分区：
文献类型：
--
作者：
L. Holm;I. Dahlqvist;A. Israelsson;G. Lundell
我们研究了2727例甲状腺功能亢进症患者和273例甲状腺功能正常的心脏病患者131 I治疗后甲状腺恶性肿瘤的发生率。患者均为成年人，平均年龄57岁。131I治疗是在1951年至1965年之间进行的。甲亢患者的平均随访期为13年（85%的患者存活超过5年，平均随访期为15年），心脏病患者的平均随访期为6年（41%的患者存活超过5年，平均随访期为12年）。恶性甲状腺肿瘤的发生率是基于瑞典癌症登记处对3000例患者中任何一例发生此类肿瘤的检索。目前，131I治疗后恶性甲状腺肿瘤的发病率没有增加（观察到4例，预期为3.2例）。
We studied the incidence of malignant thyroid tumors after 131I therapy in 2727 patients with hyperthyroidism and in 273 euthyroid patients with cardiac disease. The patients were all adults, with a mean age of 57 years. The 131I therapy was given between 1951 and 1965. The mean follow-up period was 13 years for the hyperthyroid patients (15 years for the 85 per cent surviving for more than five years) and six years for the cardiac patients (12 years for the 41 per cent surviving for more than five years). The incidence of malignant thyroid tumors was based on a search of the Swedish Cancer Registry for the occurrence of such tumors in any of the 3000 patients. At present there is no increased incidence of malignant thyroid tumors after 131I therapy (four cases observed versus 3.2 cases expected).